There has been a big community response to the Foundation’s campaign to allow AMD drug “switching”.
Macular Degeneration Foundation has announced, as part of World Sight Day activities, the winners of the mEYE World Photographic Competition 2012.
The Macular Degeneration Foundation has launched a new national awareness campaign that featured symptom recognition.
International experts met in Sydney in 2012 to develop a road map for the management of wet age-related macular degeneration.
With a new treatment for wet AMD coming on the market, drug switching between Lucentis and Eylea should be allowed.
Research has revealed Australians significantly underestimate the role of family history in developing macular degeneration.
Macular Degeneration Foundation believes a cap on the Medicare item number for the treatment of wet AMD should have minimal impact on patients.
The TGA has approved a new drug, Eylea, for the treatment of wet (neovascular) age-related macular degeneration.
ABC to trial audio description on television to assist people who are blind or visually impaired.